Long-term safety and efficacy study of a medical device containing xyloglucan, pea protein reticulated with tannins and xylo-oligosaccharides, in patients with diarrhoea-predominant irritable bowel syndrome
| Autor: | Carlos Teruel, Blanca Serrano Falcón, Esperanza Pérez, Enrique Rey, Constanza Ciriza de los Ríos, Fernando Geijo, Federico Argüelles-Arias |
|---|---|
| Přispěvatelé: | Universidad de Sevilla. Departamento de Medicina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
mucoprotectants RC799-869 Gastroenterology chemistry.chemical_compound xyloglucan Internal medicine medicine Gut permeability In patient xylo-oligosaccharides Irritable bowel syndrome Original Research irritable bowel syndrome business.industry Pea protein Diseases of the digestive system. Gastroenterology medicine.disease Pathophysiology diarrhoea Xyloglucan chemistry gut permeability Long term safety business Efficacy Study |
| Zdroj: | Therapeutic Advances in Gastroenterology, Vol 14 (2021) Therapeutic Advances in Gastroenterology |
| ISSN: | 1756-2848 |
| DOI: | 10.1177/17562848211020570 |
| Popis: | Background: Irritable bowel syndrome with diarrhoea (IBS-D) is a frequent problem associated with a significant socioeconomic implication. Increased gut permeability is an important pathophysiological mechanism. A medical device containing xyloglucan (XG), pea protein and tannins (PPT) from grape-seed extract, and xylo-oligosaccharides (XOS) has proven restoration of intestinal barrier function. Our objective was to evaluate the efficacy and safety of treatment with the medical device XG + PPT + XOS (XG-PPT-XOS) in adult patients with IBS-D in a clinical setting for 6 months. Material and methods: This was a multicentre, open-label, prospective, observational study conducted to evaluate long-term safety and efficacy of XG-PPT-XOS. IBS-D adult patients (Rome IV criteria) were included and received two tablets twice daily for 6 months. IBS Symptom Severity Score (IBS-SSS) and bowel habit were registered at baseline and monthly, until the end of follow up. Efficacy was evaluated by comparison of mean scores at each time point. Results: 50 patients were included, of which 19 completed the 6 months. IBS-SSS score decreased from 312.2 ± 82.2 to 213.6 ± 109.9 ( p Conclusion: Treating IBS-D patients with XG-PPT-XOS is effective and safe in the long term within a clinical setting, improving all IBS-D symptoms from the first month of treatment and showing a sustained response over the term of therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|